Novartis’s $5.3 Billion Eye Disease Deal Adds Cash for Bigger Bets 

(Bloomberg) -- While Novartis AG bets on cutting-edge science in pursuit of the next breakthrough drugs, its deal to pay as much as $5.3 billion for an eye medicine adds a less risky and more predi...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.